AI Engines For more Details: Perplexity Kagi Labs You
Muscle Growth and Strength: Stanozolol is known for its anabolic effects, which promote muscle growth and increase strength. It is often used by athletes and bodybuilders to enhance performance and improve physical appearance.
Increased Red Blood Cell Production: Stanozolol can stimulate the production of red blood cells, which may improve endurance and athletic performance by increasing oxygen delivery to muscles.
Treatment of Hereditary Angioedema: In medical settings, stanozolol is used to treat hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body. Stanozolol helps reduce the frequency and severity of these episodes.
Side Effects in Men: Like other anabolic steroids, stanozolol can cause various side effects, particularly in men. These may include acne, oily skin, hair loss (alopecia), increased facial or body hair growth (hirsutism), and prostate enlargement.
Side Effects in Women: Women who use stanozolol may experience masculinizing effects, including deepening of the voice, enlargement of the clitoris, and irregular menstrual periods. These effects are irreversible in some cases.
Cardiovascular Effects: Stanozolol use has been associated with adverse cardiovascular effects, including increased risk of heart attack, stroke, and blood clots. It can also alter levels of cholesterol and triglycerides, potentially leading to atherosclerosis (hardening of the arteries).
Liver Toxicity: Stanozolol is hepatotoxic, meaning it can cause liver damage or dysfunction. Prolonged use or high doses of stanozolol may lead to liver tumors, jaundice, hepatitis, or liver failure.
Psychological Effects: Anabolic steroid use, including stanozolol, may be associated with mood changes, aggression, irritability, and other psychological effects known as "roid rage."
Dependency and Withdrawal: Long-term use of stanozolol or other anabolic steroids can lead to physical and psychological dependence. Abrupt discontinuation of stanozolol may result in withdrawal symptoms such as fatigue, depression, and decreased libido.
Legal and Ethical Issues: The non-medical use of stanozolol for performance enhancement or bodybuilding purposes is illegal in many countries and violates the rules of sports organizations and athletic competitions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 3.2 | 0.6 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 1.6 | 0.75 |
| Allergies | 4.4 | 2.4 | 0.83 |
| Allergy to milk products | 1.4 | 1 | 0.4 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 3.2 | 6.4 | -1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 0.4 | 5 |
| Ankylosing spondylitis | 2.8 | 1.5 | 0.87 |
| Anorexia Nervosa | 1.6 | 2.9 | -0.81 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
| Asthma | 4.4 | 2.4 | 0.83 |
| Atherosclerosis | 1.4 | 1.8 | -0.29 |
| Atrial fibrillation | 3.7 | 1.6 | 1.31 |
| Autism | 6.9 | 6.9 | 0 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 1.5 | 1.7 | -0.13 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Cancer (General) | 0.6 | 2 | -2.33 |
| Carcinoma | 3.2 | 2.6 | 0.23 |
| Celiac Disease | 2 | 3.1 | -0.55 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 3.4 | 5.6 | -0.65 |
| Chronic Kidney Disease | 3.7 | 2.6 | 0.42 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.6 | 1.7 | -0.06 |
| Chronic Urticaria (Hives) | 0.8 | 0.4 | 1 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 4.7 | 1.9 | 1.47 |
| Constipation | 0.9 | 0.7 | 0.29 |
| Coronary artery disease | 1.8 | 2.7 | -0.5 |
| COVID-19 | 6.2 | 10.1 | -0.63 |
| Crohn's Disease | 5.7 | 5.3 | 0.08 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 0.6 | 1.4 | -1.33 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 7.1 | 8.7 | -0.23 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 2.3 | -0.64 |
| Endometriosis | 2.3 | 2 | 0.15 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.2 | 1.5 | 0.47 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 3.1 | 1.4 | 1.21 |
| Functional constipation / chronic idiopathic constipation | 3.7 | 3.5 | 0.06 |
| gallstone disease (gsd) | 2.8 | 0.9 | 2.11 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 1.2 | -1 |
| Generalized anxiety disorder | 1.9 | 1.6 | 0.19 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.3 | 0.5 | 1.6 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 0.7 | 0.29 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.3 | 1.5 | 1.2 |
| Heart Failure | 3.1 | 1.9 | 0.63 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
| hyperglycemia | 1.4 | 1.3 | 0.08 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.8 | 4.7 | -0.24 |
| Hypothyroidism | 0 | 1 | 0 |
| Hypoxia | 2.4 | 0.3 | 7 |
| IgA nephropathy (IgAN) | 1.6 | 2.7 | -0.69 |
| Inflammatory Bowel Disease | 5.8 | 8 | -0.38 |
| Insomnia | 2.5 | 2.5 | 0 |
| Intelligence | 0.8 | 0.8 | |
| Intracranial aneurysms | 1.2 | 0.6 | 1 |
| Irritable Bowel Syndrome | 5.5 | 3.6 | 0.53 |
| ischemic stroke | 2.2 | 1.1 | 1 |
| Liver Cirrhosis | 6.2 | 3.8 | 0.63 |
| Long COVID | 5.1 | 7.3 | -0.43 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.2 | 1.1 | -4.5 |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 0.5 | 2.4 | -3.8 |
| ME/CFS without IBS | 1.5 | 2 | -0.33 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.1 | 0.6 | 0.83 |
| Metabolic Syndrome | 5.9 | 6.1 | -0.03 |
| Mood Disorders | 7.3 | 6.6 | 0.11 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 4.9 | 5.7 | -0.16 |
| Multiple system atrophy (MSA) | 0.9 | 0.7 | 0.29 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 2.9 | -8.67 |
| Neuropathy (all types) | 0.7 | 1.4 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.7 | 4.5 | -0.22 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 8.9 | 7.9 | 0.13 |
| obsessive-compulsive disorder | 3.2 | 3.7 | -0.16 |
| Osteoarthritis | 2 | 1.2 | 0.67 |
| Osteoporosis | 1.9 | 1.4 | 0.36 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7.3 | 6.3 | 0.16 |
| Polycystic ovary syndrome | 5.3 | 3 | 0.77 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 0.8 | 0.5 |
| Primary sclerosing cholangitis | 1.9 | 2.8 | -0.47 |
| Psoriasis | 3 | 2.5 | 0.2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.7 | 4.1 | 0.63 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 5.4 | 3.1 | 0.74 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 1.6 | 2.6 | -0.63 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.2 | 6 |
| Stress / posttraumatic stress disorder | 2.4 | 2.3 | 0.04 |
| Systemic Lupus Erythematosus | 3.4 | 2.4 | 0.42 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.1 | 3.4 | -0.62 |
| Type 2 Diabetes | 6 | 5 | 0.2 |
| Ulcerative colitis | 4.1 | 3.7 | 0.11 |
| Unhealthy Ageing | 3.6 | 2.5 | 0.44 |
| Vitiligo | 2.2 | 1.6 | 0.38 |
